Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 4/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.42 |
| ▸ | FAP | Q12884 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | FPR1 | P21462 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12173472 | 0.87 | PPARG (0.47) | DPP4DPP8DPP9FAPLMNA | |
| SCHEMBL13516020 | 0.82 | PPARG (0.41) | DPP4DPP8DPP9FAPPPARG | |
| SCHEMBL13734997 | 0.77 | CTSC (0.50) | — | |
| Water SCHEMBL6343486 | 0.77 | CTSC (0.50) | — | |
| SCHEMBL1245187 | 0.77 | CTSC (0.50) | — | |
| SCHEMBL6688791 | 0.77 | PPARG (0.49) | DPP4LMNAPPARGPPARAMAOB | |
| SCHEMBL14720120 | 0.76 | PNMT (0.41) | ALDH1A1MEN1MAPTKMT2ANPSR1 | |
| SCHEMBL198401 | 0.75 | DPP4 (0.40) | DPP4DPP8DPP9FAPLMNA | |
| SCHEMBL31112170 | 0.75 | PPARG (0.44) | DPP4LMNAPPARGPPARAMAOB | |
| SCHEMBL9817764 | 0.75 | PPARG (0.44) | DPP4LMNAPPARGPPARAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096605-B2 | Pyrazolopyrimidine derivatives as PI3 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096605-B2 | Pyrazolopyrimidine derivatives as PI3 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096605-B2 | Pyrazolopyrimidine derivatives as PI3 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140187545-A1 | Pyrazolopyrimidine Derivatives As PI3 Kinase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140187545-A1 | Pyrazolopyrimidine Derivatives As PI3 Kinase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140187545-A1 | Pyrazolopyrimidine Derivatives As PI3 Kinase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-07-03 | — | — | US | disclosed |
| WO-2013028263-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-02-28 | — | — | WO | disclosed |
| WO-2013028263-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140187545-A1 | Pyrazolopyrimidine Derivatives As PI3 Kinase Inhibitors | PI4KB, PIK3CA, PI4K2B | DPP4 769/4885DPP8 773/4885DPP9 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.